Sudarshan Pharma Approves Acquisition of 9.5% Stake in MedTherapy Biotechnology
Sudarshan Pharma Industries approved acquiring a 9.5% stake in MedTherapy Biotechnology Inc., a Boston-based cancer cell gene therapy company, aiming to enter the US market. The acquisition involves purchasing over 24 lakh shares for a cash consideration in US dollars, expected to complete by March 31, 2027, subject to regulatory approvals. Promoters Hemal Mehta and Sachin Mehta will acquire an additional 1.5% stake. The move provides access to MedTherapy's customer base and supports expansion into new products and services.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (60/100). Lens Score 38/100.
Outlets measured: indiatvnews, mint. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
mint broke this story on 6 Sept, 10:19 am. Other outlets followed.